Source comparison
Comparison: Sermorelin vs Other GH Stimulation Methods
Sermorelin Acetate GHRH receptor agonist. Stimulates endogenous pituitary GH release 5–7 days for initial pulse increase; 4–6 weeks for sustained elevation Improved sleep depth, minor energy shifts, mild water retention Moderate fat loss, lean mass preservatio
This comparison does not assign a generated winner or score.
- Sermorelin Acetate
- GHRH receptor agonist. Stimulates endogenous pituitary GH release
- 5–7 days for initial pulse increase; 4–6 weeks for sustained elevation
- Improved sleep depth, minor energy shifts, mild water retention
- Moderate fat loss, lean mass preservation, collagen synthesis over 12–20 weeks
- Best for physiological restoration with preserved pituitary function; slower onset but sustainable long-term
- Exogenous GH (recombinant human GH)
- Direct GH replacement. Bypasses pituitary entirely
- Immediate (within 24–48 hours)
- Rapid water retention, energy increase, potential hypoglycemia
- Significant fat loss and muscle gain within 8–12 weeks, but suppresses endogenous production
- Faster results but higher risk of axis suppression and side effects; not suitable for long-term use without cycling
- GHRP-2 / GHRP-6 (GH-releasing peptides)
- Ghrelin receptor agonist. Stimulates GH release through different pathway than GHRH
- 3–5 days for GH pulse increase
- Increased appetite, minor water retention, energy variability
- Moderate anabolic effect; synergistic when combined with sermorelin
- Stronger GH pulse than sermorelin alone but higher appetite stimulation; often stacked with GHRH analogs
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic. Stimulates GH and IGF-1 through ghrelin pathway
- 7–14 days for GH and IGF-1 rise
- Increased appetite, mild water retention, improved sleep in some users
- Moderate fat loss and lean mass gain over 12–16 weeks; sustained IGF-1 elevation
- Convenient oral administration but less precise GH pulsatility; can cause persistent hunger and insulin resistance with prolonged use